Afshin Derakhshani

Dr. Afshin Derakhshani

Laboratory of Experimental Pharmacology, IRCCS, Istituto Tumori Giovanni Paolo II, 70124 Bari, Italy

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
GCGlobal Burden of Disease Cancer Collaboration
Global Burden of Disease Cancer Collaboration
CFChristina Fitzmaurice
Christina Fitzmaurice
DADegu Abate
Degu Abate
NANaghmeh Abbasi
Naghmeh Abbasi
HAHedayat Abbastabar
Hedayat Abbastabar
CMChristopher J. L. Murray
Christopher J. L. Murray
Cancer is now widely recognized as a global problem that unfortunately lacks a global solution. The latest United Nations high-level meeting on noncommunicable diseases (NCDs) exemplified this conundrum.1 Despite global commitment to reducing the risk of and disability from NCDs, including cancer, implementation of known solutions is inadequate to reach the 2011 Political Declaration on the Prevention and Control of Noncommunicable Diseases2,3 (25% reduction in premature mortality from NCDs by 2025) and the third Sustainable Development Goal (by 2030 reduce by one-third premature mortality from NCDs through prevention and treatment, and promote mental health and well-being).4 To reduce cancer burden, identifying the scope of the problem and mapping out implementation of solutions is best done in National Cancer Control Plans (NCCPs). However, a recent review showed that only 29% of low-income countries had a NCCP, and even if NCCPs existed, cost, financing, monitoring, and expansion of information systems was often inadequate. Many highly effective prevention and treatment strategies exist for cancer. However, they are often very specific (eg, vaccination for human papillomavirus and hepatitis B virus for prevention of cervical and liver cancer, or tyrosine kinase inhibitors for cancers with targetable mutations). Effective NCCPs therefore require detailed knowledge about the local burden of cancer and associated risk factors. We herein present results from the Global Burden of Disease (GBD) 2017 study describing cancer incidence, mortality, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life-years (DALYs) for 195 countries from 1990 through 2017, which can inform cancer control through policy, resource allocation, and health system planning.

23 April 2020 in Cancers
Verified
Journal Article
Open access
PDF file
ZAzahra asadzadeh
zahra asadzadeh
ESElham Safarzadeh
Elham Safarzadeh
SSSaeed Solali
Saeed Solali
ABAli Baradaran
Ali Baradaran
AMAli Mohammadi
Ali Mohammadi
Behzad BaradaranBehzad Baradaran
Behzad Baradaran
Cell death resistance is a key feature of tumor cells. One of the main anticancer therapies is increasing the susceptibility of cells to death. Cancer cells have developed a capability of tumor immune escape. Hence, restoring the immunogenicity of cancer cells can be suggested as an effective approach against cancer. Accumulating evidence proposes that several anticancer agents provoke the release of danger-associated molecular patterns (DAMPs) that are determinants of immunogenicity and stimulate immunogenic cell death (ICD). It has been suggested that ICD inducers are two different types according to their various activities. Here, we review the well-characterized DAMPs and focus on the different types of ICD inducers and recent combination therapies that can augment the immunogenicity of cancer cells.

Verified
Journal Article
Open access
PDF file
OKomid kooshkaki
omid kooshkaki
ADAfshin Derakhshani
Afshin Derakhshani
NHnegar hosseinkhani
negar hosseinkhani
MTMitra Torabi
Mitra Torabi
SSSaeed Solali
Saeed Solali
Behzad BaradaranBehzad Baradaran
Behzad Baradaran
Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) are inhibitory checkpoints that are commonly seen on activated T cells and have been offered as promising targets for the treatment of cancers. Immune checkpoint inhibitors (ICIs)targeting PD-1, including pembrolizumab and nivolumab, and those targeting its ligand PD-L1, including avelumab, atezolizumab, and durvalumab, and two drugs targeting CTLA-4, including ipilimumab and tremelimumab have been approved for the treatment of several cancers and many others are under investigating in advanced trial phases. ICIs increased antitumor T cells’ responses and showed a key role in reducing the acquired immune system tolerance which is overexpressed by cancer and tumor microenvironment. However, 50% of patients could not benefit from ICIs monotherapy. To overcome this, a combination of ipilimumab and nivolumab is frequently investigated as an approach to improve oncological outcomes. Despite promising results for the combination of ipilimumab and nivolumab, safety concerns slowed down the development of such strategies. Herein, we review data concerning the clinical activity and the adverse events of ipilimumab and nivolumab combination therapy, assessing ongoing clinical trials to identify clinical outlines that may support combination therapy as an effective treatment. To the best of our knowledge, this paper is one of the first studies to evaluate the efficacy and safety of ipilimumab and nivolumab combination therapy in several cancers.

30 September 2019 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
ADAfshin Derakhshani
Afshin Derakhshani
ZRZohreh Rezaei
Zohreh Rezaei
HSHossein Safarpour
Hossein Safarpour
MSMorteza Sabri
Morteza Sabri
AMAtefeh Mir
Atefeh Mir
Behzad BaradaranBehzad Baradaran
Behzad Baradaran

1 May 2019 in Immunology Letters
Verified
Journal Article
Closed access
ADAfshin Derakhshani
Afshin Derakhshani
FVFatemeh Vahidian
Fatemeh Vahidian
MAMohammad Alihasanzadeh
Mohammad Alihasanzadeh
AMAhad Mokhtarzadeh
Ahad Mokhtarzadeh
PNParisa Lotfi Nezhad
Parisa Lotfi Nezhad
Behzad BaradaranBehzad Baradaran
Behzad Baradaran

Verified
Journal Article
Open access
PDF file
NHnegar hosseinkhani
negar hosseinkhani
ADAfshin Derakhshani
Afshin Derakhshani
OKomid kooshkaki
omid kooshkaki
MSMahdi Abdoli Shadbad
Mahdi Abdoli Shadbad
Khalil HajiasgharzadehKhalil Hajiasgharzadeh
Khalil Hajiasgharzadeh
Behzad BaradaranBehzad Baradaran
Behzad Baradaran
Although the ever-increasing number of cancer patients pose substantial challenges worldwide, finding a treatment with the highest response rate and the lowest number of side effects is still undergoing research. Compared to chemotherapy, the relatively low side effects of cancer immunotherapy have provided ample opportunity for immunotherapy to become a promising approach for patients with malignancy. However, the clinical translation of immune-based therapies requires robust anti-tumoral immune responses. Immune checkpoints have substantial roles in the induction of an immunosuppressive tumor microenvironment and tolerance against tumor antigens. Identifying and targeting these inhibitory axes, which can be established between tumor cells and tumor-infiltrating lymphocytes, can facilitate the development of anti-tumoral immune responses. Bispecific T-cell engagers, which can attract lymphocytes to the tumor microenvironment, have also paved the road for immunological-based tumor elimination. The development of CAR-T cells and their gene editing have brought ample opportunity to recognize tumor antigens, independent from immune checkpoints and the major histocompatibility complex (MHC). Indeed, there have been remarkable advances in developing various CAR-T cells to target tumoral cells. Knockout of immune checkpoints via gene editing in CAR-T cells might be designated for a breakthrough for patients with malignancy. In the midst of this fast progress in cancer immunotherapies, there is a need to provide up-to-date information regarding immune checkpoints, bispecific T-cell engagers, and CAR-T cells. Therefore, this review aims to provide recent findings of immune checkpoints, bispecific T-cell engagers, and CAR-T cells in cancer immunotherapy and discuss the pertained clinical trials.